Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Hepatitis B vaccine for inducing organism to generate specific immunity in state of chronic hepatitis B virus infection

A technology of hepatitis B vaccine and chronic hepatitis B, which is applied in antiviral agents, antibody medical ingredients, medical preparations containing active ingredients, etc.

Active Publication Date: 2014-02-12
李金秋
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, for hepatitis B therapeutic vaccine, the use of aluminum adjuvant alone is not enough

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Hepatitis B vaccine for inducing organism to generate specific immunity in state of chronic hepatitis B virus infection
  • Hepatitis B vaccine for inducing organism to generate specific immunity in state of chronic hepatitis B virus infection
  • Hepatitis B vaccine for inducing organism to generate specific immunity in state of chronic hepatitis B virus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0063] Example 1: The combination method of CL097 and aluminum adjuvant:

[0064] Preparation method 1:

[0065] Al and antigen were mixed for 30 minutes at room temperature

[0066] Mix Al and CL097 at room temperature for 30 minutes

[0067] The two are then mixed,

[0068] The free CL097 measured by mass spectrometry is 41% of the total amount added

[0069] The estimated binding capacity was 59%.

[0070] Preparation method 2:

[0071] Al and CL097 were first mixed at room temperature for 15 minutes,

[0072] Add antigen and keep at room temperature for 10 minutes,

[0073] The free CL097 of mass spectrometry is 42% of the total amount added,

[0074] The estimated binding capacity is 58%.

[0075] Preparation method 3:

[0076] Al and antigen were first mixed at room temperature for 30 minutes,

[0077] Then add CL097 at room temperature for 10 minutes,

[0078] The free CL097 measured by mass spectrometry is 44% of the total amount added,

[0079] The estimat...

Embodiment 2

[0081] Example 2: Effects of CL097 combined with HBsAg and / or HBcAg on the humoral immune response of C57 / B6J mice

[0082] 1. Experimental animal: C57 / B6J mouse (purchased from Beijing Huafukang Biotechnology Co., Ltd., male, date of birth: March 14-21, 2012)

[0083] 2. Reagents:

[0084] 1) Hepatitis B virus surface antibody quantitative assay kit (enzyme-linked immunoassay): purchased from Beijing Wantai Biopharmaceutical Co., Ltd. (batch number: R20110905).

[0085] 2) Hepatitis B virus core antibody diagnostic kit (enzyme-linked immunoassay): purchased from Shanghai Kehua Bioengineering Co., Ltd. (batch number: 201203031). The competition method is used for detection. If the anti-HBc content in the sample to be tested is high, the absorbance value will be low, which may easily cause understanding errors. In order to avoid this situation, we use the upper limit of absorbance detection 4 to subtract the actual detection result. absorbance as its relative titer).

[0086...

Embodiment 3

[0103] Embodiment 3: CL097 combined with HBsAg / HBcAg can break the immune tolerance of HBV transgenic mice

[0104] 1. Experimental animal: C57BL / BJ-TgN(AlblHBV)44Bri mouse, which is a kind of HBV transgenic mouse, carries the genes encoding the S, PreS1, PreS2 and HBx regions of HBV, and can be detected in serum, liver and kidney HBsAg was expressed in the mouse, but there was no virus replication (purchased from the Experimental Animal Center of Peking University Health Science Center, male, mouse birth date: September 21-28, 2011).

[0105] 2. Reagents:

[0106] 1) Hepatitis B virus surface antibody quantitative assay kit (enzyme-linked immunoassay): purchased from Beijing Wantai Biopharmaceutical Co., Ltd. (batch number: R20110905);

[0107] 2) Hepatitis B virus surface antigen diagnostic kit (enzyme-linked immunoassay): purchased from Shanghai Kehua Bioengineering Co., Ltd. (batch number: 201110031);

[0108]3) Alanine aminotransferase assay kit (rate method): purchased...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a hepatitis B vaccine, and in particular discloses a hepatitis B vaccine which contains an immunopotentiator and can induce an organism to generate specific immunity in a state of chronic hepatitis B virus infection. The hepatitis B vaccine disclosed by the invention contains a Toll-like receptor agonist serving as the immunopotentiator.

Description

technical field [0001] The present invention relates to hepatitis B vaccine. Specifically, the present invention relates to a hepatitis B vaccine containing an immune enhancer, which can induce the body to produce a specific immune response in the state of chronic hepatitis B virus infection. The hepatitis B vaccine of the present invention contains an agonist of Toll-like receptor as an immune enhancer. In addition, the present invention also relates to the use of the agonist of Toll-like receptor as an immune enhancer in hepatitis B vaccine. Background technique [0002] In China, hepatitis B virus (HBV) infection has become one of the most serious public health problems, and about 60% of the population has been infected with HBV. According to the national epidemiological survey in 2006, the carrier rate of chronic hepatitis B surface antigen (HBsAg) in China is still as high as 7.2%, and there are about 93 million HBV infected patients and 30 million chronic hepatitis B...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/39A61K39/29A61P31/20
Inventor 曲春枫汪颖吴志远
Owner 李金秋
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com